Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sleep apnea therapy may lower cell damage in heart patients

NCT ID NCT02893865

Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 28 people with both stable coronary artery disease and moderate sleep apnea. Researchers measured blood markers of oxidative stress (a type of cell damage) before and after 3 months of CPAP therapy. The goal was to see if CPAP could reduce oxidative stress, which might help explain how sleep apnea affects heart health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

28 people

The number who actually took part.

Started

May 2016

Finished

Jul 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Apnea Hypopnea Index 15-30/h * Stable Coronary artery disease * Obligation of obtaining informed consent form Exclusion Criteria: * Heart failure with LVEF less than or equal to 45% * Other Chronic disease: renal failure, COPD Index - central apneas than or equal to 50% of the total IAH * treatment with CPAP or mandibular advancement device * IMC\> 40 kg / m² * Nutritional supplementation in the 4 weeks preceding the study (antioxidants, vitamins ...). * Treatment with allopurinol or N-acetylcysteine, in the 4 weeks preceding the study. * PaCO2\> 45 mmHg - Counter-indication to the use of PPC: bullous lung disease, pathological hypotension, bypass airway, pneumothorax, signs of sinus infections or inner ear * Exclusion period on subject compared to another protocol or for which the maximum annual amount of compensation of € 4,500 has been reached. * Participation of the subject to another study. * Not affiliated with a social security scheme subject or not the beneficiary of such a regime. * Pregnant or breastfeeding women, patient unable to give consent, protected adult, vulnerable * Subject deprived of liberty by judicial or administrative decision * HIV infection, hepatitis B or hepatitis C known

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder obstructive sleep apnea syndrome sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Sleep apnea syndrome

Contacts and locations

Locations

  • CHU of Montpellier

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.